Celsion’s ThermoDox in combination treatment improves survival by more than 50%
US cancer drug developer Celsion Corp (Nasdaq: CLSN) says that the latest overall survival data from its Phase III HEAT study of ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radio frequency ablation (RFA) in liver cancer supports its continued clinical development. Shares of the company dropped 2.2% to $3.75 in mid-morning trading on the news.
This analysis followed the announcement on January 31, 2013, that the HEAT Study did not meet its primary endpoint of progression-free survival (PFS). As provided for in the HEAT study's Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration, the company continues to follow patients for overall survival, the secondary endpoint of the study. Data from four quarterly reviews of overall survival have been evaluated since the announcement of top line PFS data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze